Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST

BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!

  • Biotechnology
  • Pharma

Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?

Read

Commented by Fabian Lorenz on May 3rd, 2023 | 07:30 CEST

Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates

  • Biotechnology
  • Pharma
  • Innovations

Things can move fast in the biotech sector. The share price of Prometheus Biosciences shot up by a good 75% practically overnight. The reason: US pharmaceutical group Merck & Co wants to buy the Company specializing in treating immune diseases, thus strengthening its own product portfolio. Thanks to clever takeovers, Sartorius has also grown strongly in recent years, become a success story on the German stock market and risen to the DAX. The latest acquisition of the laboratory supplier is Polyplus. The French company develops DNA and RNA components for cell and gene therapies. Is BioNxt, also active in Germany, the next takeover candidate? In any case, the Company is taking big steps towards commercialization. Investors are also hoping for new impetus from Bayer and BioNTech. Both companies have important dates coming up. But analysts are skeptical.

Read

Commented by Armin Schulz on April 24th, 2023 | 08:30 CEST

BioNTech, Defence Therapeutics, Sartorius - Takeover fever in the biotech sector

  • Biotechnology
  • Pharma
  • vaccine
  • Cancer

In the past year, the NASDAQ Biotechnology Index took a severe beating until mid-June. In the meantime, an initial upward trend has developed, and the market is slowly heating up again because some biotech companies are still valued too cheaply. This is when the big players strike, such as Merck & Co, which recently bought Prometheus Biosciences for USD 10.8 billion. The buyer thus paid a premium of a whopping 75% on the previous day's closing price. The biotech start-up Tubulis has also agreed on a collaboration with Bristol-Myers Squibb that could bring more than USD 1 billion into the Munich-based company's coffers. Reason enough to take a look at three companies from the pharmaceutical and biotech sector.

Read

Commented by André Will-Laudien on April 12th, 2023 | 10:34 CEST

Attention, biotech is back! Bayer, Defence Therapeutics, BioNTech - These stocks are breaking out!

  • Biotechnology
  • Pharma
  • Cancer
  • mRNA

For months the market did not care about biotech stocks. But now technical bottoms have been reached, and a rise is likely. In this context, the capital market interest rate is important: if it falls due to increased fears of recession, there is no stopping the biotechs because refinancing costs fall. Sentiment measurements over Easter showed that the risk bias of investors has also returned. If not now, then when, the moment is favorable! Shortlist the following stocks.

Read

Commented by Armin Schulz on April 5th, 2023 | 12:25 CEST

BioNTech, BioNxt Solutions, Bayer - The big one is only a matter of time

  • Biotechnology
  • Pharma
  • Cancer

The biotech and pharmaceutical industry is currently in a constant state of flux, driven by the introduction of new technologies and the fight against global health problems. Producing medicines and therapies to alleviate diseases is of great value to people's health. Against the backdrop of an ageing population in industrialised nations, the sector will continue to be of great importance. A particular focus is on inventing advanced technologies to fight diseases such as cancer, Alzheimer's and Parkinson's. Today we look at three companies in the biotech and pharma sector.

Read

Commented by Nico Popp on April 4th, 2023 | 17:04 CEST

Race against cancer: BioNTech, Bayer, Defence Therapeutics

  • Biotechnology
  • Cancer

BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.

Read

Commented by Nico Popp on March 27th, 2023 | 09:26 CEST

Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech

  • Biotechnology
  • Pharma

What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.

Read

Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET

BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential

  • Biotechnology
  • research
  • Pharma

The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.

Read

Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET

Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?

  • Biotechnology
  • Takeover

Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.

Read

Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET

Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!

  • Biotechnology
  • vaccine
  • Covid19

The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!

Read